CoChat
Sign Up
Cited by 98Psychedelics and Drug StudiesTreatment of Major DepressionReligion, Spirituality, and Psychology

Registered clinical studies investigating psychedelic drugs for psychiatric disorders

Siegel, Ashley N., Meshkat, Shakila, Benitah, Katie, Lipsitz, Orly, Gill, Hartej, Lui, Leanna M.W., Teopiz, Kayla M., McIntyre, Roger S. +1 more·2021·Journal of Psychiatric Research
DOI 10.1016/j.jpsychires.2021.05.019
Open this paper in CoChat — free account

Abstract

Psychedelics are a hallucinogenic class of psychoactive drugs with the primary effect of activating non-ordinary states of consciousness. Due to the positive preliminary findings of these drugs in the treatment of psychiatric disorders, the number of registered clinical studies has risen significantly. In this paper, clinical studies registered on clinicaltrials.gov that evaluate the treatment of any psychiatric disorder with psychedelics (excluding ketamine) are summarized and analyzed. 70 registered studies were identified from a clinicaltrials.gov search on December 3, 2020. The majority of studies aim to investigate methylenedioxymethamphetamine (MDMA) (45.7%) and psilocybin (41.4%). Studies evaluating ayahuasca, lysergic acid diethylamide (LSD), ibogaine hydrochloride, salvia divinorum, 5-MeO-DMT and DMT fumarate were less common at 1.4%, 4.2%, 2.8%, 1.4%, 1.4% and 1.4% of total registered studies, respectively. Most of the studies on MDMA, psilocybin, ayahuasca and salvia divinorum investigated their therapeutic effect on post-traumatic stress disorder (PTSD) and major depressive disorder (MDD). LSD was investigated for MDD, anxiety, and severe somatic disorders and ibogaine hydrochloride was investigated for substance and alcohol use disorders. 5-MeO-DMT and DMT fumarate were both investigated for MDD. Only 21/70 registered studies had published results with the majority not yet completed. In view of the large number of ongoing studies investigating psychedelics, it is imperative that these studies are considered by researchers and stakeholders in deciding the most relevant research priorities for future proposed studies.

Integrity signals

Registry

Crossref · 10.1016/j.jpsychires.2021.05.019

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Classical psychedelics induce altered states of consciousness primarily by interacting with 5-HT2A receptors.

    “These compounds induce altered states of consciousness primarily by interacting with the 5-HT2A receptors”

    From A Narrative Review of Current and Emerging Trends in the Treatment of Alcohol Use Disorder (2024) · cites this paper as [73]

  • Non-classic psychedelics (e.g., ketamine, MDMA, ibogaine, salvinorin A, THC) work through distinct mechanisms and can significantly change consciousness.

    “Non-classic psychedelics, on the other hand, work through various mechanisms. For example, ketamine blocks NMDA receptors, MDMA influences serotonin and dopamine, ibogaine has multiple targets, salvinorin A stimulates kappa-opioid receptors, and delta-9-tetrahydrocannabinol (THC), found in cannabis, acts on cannabinoid receptors. These substances, like classic psychedelics, can change”

    From A Narrative Review of Current and Emerging Trends in the Treatment of Alcohol Use Disorder (2024) · cites this paper as [73]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Siegel, A. N., Meshkat, S., Benitah, K., Lipsitz, O., Gill, H., Lui, L. M. W., Teopiz, K. M., McIntyre, R. S., & Rosenblat, J. D.
Affiliations
University Health Network (CA)
Corresponding author
Rosenblat, Joshua D.
ORCID
Venue
Journal of Psychiatric Research
Publisher
Elsevier BV
Published
2021-07
Volume
139
Pages
71-81
ISSN
0022-3956 (ISSN-L)
DOI
10.1016/j.jpsychires.2021.05.019
OpenAlex
W3160765419
Cited by
97
References
23
Citations by year
2026: 11 · 2025: 16 · 2024: 24 · 2023: 18 · 2022: 25 · 2021: 3
FWCI
12.28
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Journal of Psychiatric Research (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
  • Social Sciences › Health › Religion, Spirituality, and Psychology
Keywords
psychedelics, mental illness, MDMA, psilocybin, ayahuasca, LSD, ibogaine, Salvia divinorum, 5-MeO-DMT, post-traumatic stress disorder, major depressive disorder, anxiety, substance use disorders, alcoholism, research priorities, clinical trial registration
MeSH terms
Alcoholism, Depressive Disorder, Major, Major Depressive Disorder, Pharmaceutical Preparations, Hallucinogens, Humans, Psilocybin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review